Last reviewed · How we verify
CYP3A4 probe
At a glance
| Generic name | CYP3A4 probe |
|---|---|
| Also known as | Midazolam (2mg) |
| Sponsor | Repros Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies (PHASE4)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
- Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects (PHASE1)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity (PHASE1)
- Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics (PHASE1)
- To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (PHASE1)
- Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYP3A4 probe CI brief — competitive landscape report
- CYP3A4 probe updates RSS · CI watch RSS
- Repros Therapeutics Inc. portfolio CI